QUCY
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No Graham Number available; valuation metrics are disconnected from fundamental performance.
- Price/Book of 7.38 is excessive for a distressed firm
- Price/Sales of 11.35 is unsustainable given revenue decline
Growth metrics are negative across primary revenue streams.
- EPS is becoming 'less negative'
- Revenue growth is -32.90%
- No clear path to profitability
Consistent and severe destruction of shareholder value over 5 years.
- 5Y Change of -98.2%
- 1Y Change of -84.9%
Financial health is critical; company cannot cover short-term obligations.
- Piotroski F-Score 3/9 (Weak)
- Current Ratio 0.50 (Insolvent profile)
- Debt/Equity 4.01 (Over-leveraged)
Dividend Strength 0/100.
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for QUCY and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
QUCY
Mainz Biomed N.V.
Primary
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
NXGL
NEXGEL, Inc.
Peer
|
-78.5% | -49.8% | -73.0% | -70.1% | -8.6% | +18.5% |
|
MGRX
Mangoceuticals, Inc.
Peer
|
-99.3% | -97.5% | -78.4% | -84.5% | +2.4% | +2.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
NXGL
NEXGEL, Inc.
|
BEARISH | $6.41M | - | -52.7% | -26.3% | $0.76 | Compare |
|
MGRX
Mangoceuticals, Inc.
|
BEARISH | $6.67M | - | -141.7% | -% | $0.39 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning QUCY from our newsroom.